At the SCAI 2025 Scientific Sessions, two pivotal late-breaking clinical trials were presented, shedding new light on TAVR treatment for severe aortic stenosis. These studies offer valuable insights to guide decision-making for interventional cardiologists and other members of the heart team.
Key Findings:
- Single Antiplatelet Therapy (SAPT) vs. Dual Antiplatelet Therapy (DAPT)
A study presented by Dr. Francesco Pelliccia (Sapienza University, Rome) tracked over 5,000 patients undergoing femoral TAVR. Results showed that SAPT significantly reduced all-cause mortality (2.4% vs. 5.4%) and major bleeding events (0.5% vs. 1.3%) compared to DAPT. This provides evidence that SAPT should be considered the standard of care post-TAVR, even for patients with coronary artery disease (CAD). - Prosthesis-Patient Mismatch (PPM) in Female Patients
Dr. Karim Al-Azizi (Baylor Scott & White Health) presented data from over 3,000 TAVR patients, showing higher predicted PPM in women (26.2% vs. 18.2%), although measured PPM rates were similar (26.7% vs. 24.1%). The study emphasized that PPM did not affect long-term survival. Researchers also noted that self-expanding TAVR valves were associated with better outcomes.
Clinical Implications:
These findings underscore the importance of personalized treatment plans for TAVR patients, especially for women and those with high bleeding risks. Choosing the right valve type and post-procedure therapy could significantly influence patient outcomes.
Follow MEDWIRE.AI for more updates on TAVR and cardiovascular innovations.
